Immunwork, Inc. was established in October 2014 in Taipei, Taiwan. In response to business development needs, the company was invited between 2018 and 2019 to establish subsidiaries in Hong Kong and Nanjing, expanding its overseas footprint. To enhance management efficiency and better integrate group resources, the company underwent a corporate restructuring in November 2019, forming T-E Pharma Holding (registered in the Cayman Islands) as the group’s holding entity. Due to the impact of the COVID-19 pandemic, overseas operations could not be sustainably maintained. As a result, the Nanjing and Hong Kong subsidiaries were gradually downsized and deregistered. Subsequently, in November 2022, T-E Meds, Inc. was spun off as a separate entity. Currently, T-E Pharma Holding oversees two Taiwan-based subsidiaries: Immunwork, Inc. and T-E Meds, Inc.
Immunwork and T-E Meds are research-driven biotechnology companies focused on innovative drug discovery and development. Guided by the T-E drug design and powered by its proprietary “multi-arm linker” core platform, we has developed three major technology sub-platforms: the “fatty acid bundle”, the “cytotoxic drug bundle” and the “chelator bundle” platforms. These sub-platforms enable the rapid and flexible generation of diverse therapeutic molecules for a broad range of disease areas, including cancer, diabetes, obesity, fatty liver disease, and pathological thrombosis.
With a mission to develop innovative therapeutics that offer superior efficacy and safety, T-E Pharma is dedicated to improving patient outcomes worldwide and advancing toward international growth as a leading biotechnology company.